Merck announced the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck initiated with a Buy at Deutsche Bank
- Portage Biotech presents updates on its iNKT, adenosine programs at SITC
- Actinium Pharmaceuticals names Lynn Bodarky as Chief Business Officer
- Merck price target raised to $135 from $130 at Citi
- Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin